KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Long-term effect of sweeteners and sweetness enhancers on gene expression markers of adipose tissue function, adipocyte morphology, and metabolic health: a SWEET substudy. PMID 42230988 · Int J Obes (Lond) · 2026-Jun-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Adjunctive Mechanical Ventilation or Intravenous Hypertonic Saline in Malawian Children with Cerebral Malaria and Highly Increased Brain Volume: A Randomized, Phase 3 Clinical Trial. PMID 42230477 · Neurocrit Care · 2026-Jun-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of argipressin on intraoperative fluid administration in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC): study protocol of a randomised clinical trial (HiPress Trial). PMID 42229964 · BMJ Open · 2026-Jun-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of Intravenous Lidocaine, Dexmedetomidine, and Intrathecal Morphine on Metastasis-Related Biomarkers and Cellular Immune Profiles in Colorectal Surgery: A Prospective, Randomized Controlled Trial. PMID 42228944 · Anesth Analg · 2026-Jun-02 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Sentinel Node Biopsy in the Neck Management of cN0 Sinonasal Squamous Cell Carcinoma: A Multicenter Pilot Trial on Safety and Feasibility. PMID 42228262 · Ann Surg Oncol · 2026-Jun-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Determining the cutpoint of a continuous predictive biomarker via Bayesian sensitive subpopulation finding. PMID 42228058 · J Biopharm Stat · 2026-Jun-02 The record describes a Phase III randomized trial in advanced breast cancer with a time-to-event endpoint, but the publication is a methodological paper applying a new statistical method to trial data, not the original trial report. It does not explicitly state a drug intervention, and it is not a formal result report.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial. PMID 42099212 · JAMA · 2026-Jun-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Adjunctive Intra-Arterial Alteplase After Successful Thrombectomy for Acute Ischemic Stroke: The CHOICE-2 Randomized Clinical Trial. PMID 42096239 · JAMA · 2026-Jun-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparing the Recurrence Patterns of Reduced-Margins vs. RTOG-Protocol in Adjuvant Chemoradiation of High-Grade Gliomas: A Multicenter, Open-Label, Randomized Controlled Trial. PMID 42345146 · Asian Pac J Cancer Prev · 2026-Jun-01 The study meets most criteria (oncology, human, randomized, Phase III, time-to-event endpoint, original results) but does not involve a drug-containing intervention as required. The intervention compares radiation therapy margins.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial. PMID 42295761 · JAMA Netw Open · 2026-Jun-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 2 Panel · risk unclear
Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary Analysis of the INSPIRE Cluster Randomized Trials. PMID 42268612 · JAMA Netw Open · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial. PMID 42234428 · JAMA Netw Open · 2026-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer. PMID 42229584 · Ann Oncol · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Immune-inflammatory-fibrinogen score as a novel prognostic biomarker in patients with gastric cancer undergoing radical gastrectomy: a multicenter study. PMID 42226295 · World J Surg Oncol · 2026-Jun-01 The record describes a retrospective, multicenter study developing a prognostic biomarker (FSL score) and a nomogram. While the underlying data came from a randomized controlled trial, this publication is not a formal result report of that trial's intervention. It is a secondary, biomarker-focused analysis, and the drug intervention is not the subject of this efficacy evaluation.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. PMID 42225990 · Nat Med · 2026-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial. PMID 42224659 · JAMA Oncol · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. PMID 42224490 · JAMA · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Extension of the Phase 3 Trial of Somatrogon in Children with Growth Hormone Deficiency: 3 Years of Safety and Efficacy. PMID 42224388 · Horm Res Paediatr · 2026-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer. PMID 42223796 · Adv Ther · 2026-Jun-01 The record describes a real-world retrospective cross-sectional survey of treatment patterns, not a randomized clinical trial. It is not a primary result report of a Phase III/IIIb or Phase II/III randomized trial with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease. PMID 42223386 · Ophthalmology · 2026-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial. PMID 42223137 · J Clin Oncol · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. PMID 42223130 · J Clin Oncol · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
PERKS-International: A Randomized Controlled Trial Testing the Efficacy of an mHealth Application to Reduce Risk Factors for the Primary Prevention of Stroke. PMID 42220242 · Stroke · 2026-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer. PMID 42219560 · Cancer Res Commun · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 11 Panel · risk visible
Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis. PMID 42175549 · Cancer · 2026-Jun-01 While the study is from a randomized oncology trial with a drug intervention and analyzes time-to-event data, it is explicitly a secondary, post-hoc biomarker subgroup analysis, not the original primary or definitive report of the trial's main efficacy results. The phase is also not explicitly confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3. PMID 42159085 · Cancer · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Correction to: Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). PMID 42096282 · Kidney360 · 2026-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial. PMID 42060297 · JAMA Oncol · 2026-Jun-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 2 Panel · risk unclear
Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. PMID 42054033 · JAMA Cardiol · 2026-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Mailed Outreach for Colorectal Cancer Screening in Community Health Centers: The CARES Pragmatic Cluster Randomized Clinical Trial. PMID 42043827 · JAMA Intern Med · 2026-Jun-01 The trial is eligible for oncology and human subjects but is excluded because it is a cancer screening trial (not a treatment trial), the intervention is a screening modality (not a drug), and the primary efficacy endpoint is a proportion (screening participation), not a time-to-event outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial. PMID 42024409 · JAMA Ophthalmol · 2026-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cerebral Oximetry in Extremely Preterm Infants: 2-Year Follow-Up of the SafeBoosC-III Randomized Clinical Trial. PMID 42008246 · JAMA Pediatr · 2026-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Palliative Care Intervention for Patients With End-Stage Liver Disease: A Cluster Randomized Clinical Trial. PMID 41973444 · JAMA Intern Med · 2026-Jun-01 The study is an oncology-related randomized trial involving patients with hepatocellular cancer (part of the ESLD population), but it does not meet the required criteria for inclusion. The intervention is non-drug (palliative care delivery model), and the primary endpoint is quality-of-life, not a time-to-event efficacy endpoint. Mortality is reported but only as a secondary outcome with no time-to-event analysis specified.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Recombinant ADAMTS13 in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. PMID 41934124 · Blood Coagul Fibrinolysis · 2026-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial. PMID 41920558 · JAMA Psychiatry · 2026-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Results of the Pediatric Guideline Adherence and Outcomes (PEGASUS) Program Versus Usual Care Pragmatic Randomized Controlled Trial in Severe Traumatic Brain Injury. PMID 41891786 · Crit Care Med · 2026-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial. PMID 41837753 · Clin Cancer Res · 2026-Jun-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 5 Figure · 11 Panel · risk unclear
Clozapine After 1 Failed Antipsychotic Drug Trial in First-Episode Psychosis: A Randomized Clinical Trial. PMID 41811299 · JAMA Psychiatry · 2026-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study. PMID 41777218 · Inflamm Bowel Dis · 2026-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Erratum to: Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. PMID 41746815 · Neuro Oncol · 2026-Jun-01 The record is a published erratum to a trial report. It does not contain the original trial results or primary/secondary efficacy endpoint data. While the title references a Phase III RCT, the erratum itself cannot be considered the original formal-result report of the trial.
H
仅历史库存 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Hypofractionated Versus Normofractionated Accelerated Radiation Therapy With or Without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO): A Randomized, Open-Label, Phase 3, Noninferiority Trial. PMID 41711624 · Int J Radiat Oncol Biol Phys · 2026-Jun-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): A randomized, double-blind, placebo-controlled trial. PMID 41685810 · Int J Cancer · 2026-Jun-01 Trial is oncology-focused, randomized, with a drug intervention and primary results. However, it is not explicitly a Phase III/IIIb trial (phase not stated in abstract; mesh terms do not include 'Phase 3'), and crucially, the primary endpoints are incidence-based outcomes (HSIL recurrence and HPV persistence) reported as proportions and rates, not time-to-event endpoints with Kaplan-Meier curves or hazard ratios. Therefore, it fails the required time-to-event efficacy endpoint criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program. PMID 41655066 · Inflamm Bowel Dis · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of a structured exercise program on motivational outcomes in patients with colon cancer. PMID 41609410 · J Natl Cancer Inst · 2026-Jun-01 The trial is a Phase 3 randomized oncology study with human patients, but it is excluded because it does not have a drug-containing intervention (exercise program vs. health education materials) and does not report a time-to-event efficacy endpoint; it reports on motivational/behavioral outcomes.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
EHealth intervention for quality of life in long-term breast cancer survivors: randomized controlled trial. PMID 41581214 · J Natl Cancer Inst · 2026-Jun-01 The study is an oncology randomized trial reporting on quality of life, not a time-to-event efficacy endpoint. It lacks a drug intervention and is not a Phase III/IIIb or Phase II/III trial. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors. PMID 41504634 · Clin Cancer Res · 2026-Jun-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 1 Panel · risk unclear
Accelerated approvals in oncology: Trial design strategies and insights driving successful regulatory outcomes across three decades. PMID 41460153 · Int J Cancer · 2026-Jun-01 The record is a retrospective analysis of regulatory data on multiple oncology drug approvals. It does not meet the inclusion criteria for a single, original, formal-result report of a human malignant-neoplasm Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. The study design is a review of multiple trials, not a trial report itself.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
CapeOX Versus Capecitabine in Neoadjuvant Chemoradiation for High-Risk Locally Advanced Rectal Cancer: Long-Term Results From the MONT-R Randomized Controlled Trial. PMID 41352689 · Int J Radiat Oncol Biol Phys · 2026-Jun-01 The record is a randomized controlled trial in human oncology (rectal cancer) evaluating a drug intervention (CapeOX vs capecitabine) with a primary time-to-event endpoint (3-year DFS). It reports definitive long-term results and is not an interim, subgroup, or safety-only analysis. Phase III is not explicitly stated but the trial is described as a definitive, multicenter, randomized controlled trial with a large sample size (n=505) and definitive primary endpoint, qualifying as a definitive phase trial under the criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. PMID 41296499 · Diabetes Care · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group. PMID 41285272 · Int J Radiat Oncol Biol Phys · 2026-Jun-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 4 Panel · risk unclear